Q3 2008/09 presentation, 27 August 2009 By CEO Lars Marcher and CFO Anders Arvai

2 Agenda Developments in Q3 2008/09 Strategic focus areas Outlook for 2008/09

3 Highlights Overall growth satisfactory in Q3 08/09 – Ambu continues to win market share Strong growth in the USA despite economic downturn Strategic initiatives within product development, sales and streamlining taking effect Single-use videoscope Ambu aScope presented at congress in Milan in June 2009 Ambu’s new strategy plan is being prepared and will be published later this year

4 Revenue Revenue of DKK 216m in Q3 2008/09, up 10% (6% when reported in local currencies) Revenue year to date of DKK 647m, up 11% Intensified sales efforts bearing fruit Positive effect of exchange rates of approx. DKK 15m year to date

5 Revenue by business area Respiratory Care Growth of 5% year to date Lower sales of ventilation products in Spain, France and Danish Sales Other growth rates exceed market growth Still two-digit growth rates within laryngeal masks Cardiology Growth of 3% in Q3 and 8% year to date Growth generated by a broad range of products within the most important product groups Year-to-date growth in Danish Sales, Germany, Italy and the USA has been higher than market growth Neurology Strong growth of 27% in Q3 and 30% year to date Adjusted for revenue from the acquisition of Sleepmate, revenue grew 15% year to date Successful introduction of new needles DKKm Q3 2007/08 Q3 2008/09 Growth in local currencies, Q3 Growth in local currencies, YTD Share of revenue, YTD Respiratory Care %5%40% Cardiology %8%34% Neurology %30%12% Training (4%)(2%)8% Immobilization %16%6% Total %10%100%

6 Revenue by geographical region Europe Growth higher than market growth year to date Ambu maintaining its position with growth of 2% in DKK and 6% in local currencies Slight fall in revenue in Danish Sales, Spain and Benelux Development attributable to major one- off orders in Q3 2007/08 and to multiple- use products being used for longer USA Ambu continues to win market share with growth in revenue of 17% Cardiology – increased sales to rescue services and diagnostic procedures Acquisition of Sleepmate having a positive impact on growth Growth within all areas DKKm Q3 2007/08 Q3 2008/09 Growth in local currencies, Q3 Growth in local currencies, YTD Share of revenue, YTD Europe %6%62% USA %12%31% Rest of the world %18%7% Total %9%100%

7 Operating profit (EBIT) Healthy earnings of DKK 22m – however affected by higher special items and increased selling costs Effect of exchange rates, EBIT: approx. DKK -6m year to date EBIT margin of 9.6% year to date against 11.9% last year

DKKm June 2007/08 June 2008/09 Cash flows from operating activities Investments(28.9)(41.6) Acquisitions-(41.1) Free cash flow37.1(13) 8 Positive development in cash flow from operating activities Cash flows from operating activities improved in Q3 to DKK 35m against DKK 24m last year Cash flow year to date affected by the acquisition of Sleepmate Inc. and higher investments Expectations of free cash flow for 2008/09 before acquisitions continue to be approx. DKK 50m

9 Agenda Developments in Q3 2008/09 Strategic focus areas Outlook for 2008/09

10 Ambu has four focus areas Markets and sales Launch of significantly more new and differentiated products than has been the case so far Increased focus on growing markets and product areas and expanding the sales force Streamlining of important areas within the company Acquisition of new products and activities Product development Streamlining Acquisitions

11 Status on strategic initiatives (1) Product development and new products Launch of single-use videoscope Ambu aScope at the ESA congress in June 2009 aScope being matured for production, and sales expected to commence in Q1 2009/10 Development function in China is working on new versions of existing products for launch later in 2008/09 Markets and sales Expansion of the sales force in the USA and the UK is producing the expected results Implementation of several organisational changes – larger and more efficient sales organisations New sales office to be established in Australia on 1 October 2009

12 Ambu aScope New innovative single-use videoscope Combines traditional single-use technology with advanced new single-use electronics Launched at Euroanaesthesia 2009 in June 2009 For use by anaesthetists to visualise the airways of patients being anaesthetised Alternative to multiple-use fibre-optic scope Improves patient treatment and efficiency at hospitals Expected to be ready for marketing in Q1 2009/10 Estimated market size of approx. DKK 1bn

13 Status on strategic initiatives (1) Product development and new products Launch of single-use videoscope Ambu aScope at the ESA congress in June 2009 aScope being matured for production, and sales expected to commence in Q1 2009/10 Development function in China is working on new versions of existing products for launch later in 2008/09 Markets and sales Expansion of the sales force in the USA and the UK is producing the expected results Implementation of several organisational changes – larger and more efficient sales organisations New sales office to be established in Australia on 1 October 2009

14 Status on strategic initiatives (2) Streamlining New logistics planning system Roll-out of ERP system in the USA progressing according to plan and expected to be completed at the beginning of 2010 Ongoing efficiency-enhancing projects in the production units in Denmark and Asia Continued transfer of production Acquisitions Ongoing dialogue with potential candidates

15 Agenda Developments in Q3 2008/09 Strategic focus areas Outlook for 2008/09

16 Outlook for 2008/09 unchanged High level of activity and investments in the future Growth in revenue of approx. 8%, corresponding to approx. DKK 850m (USD: 550) EBIT of approx. DKK 100m before special items relating to the conduct of the pending patent cases A free cash flow in the region of DKK 50m (before acquisitions)

17 Status on patent infringement cases Patent case in the USA Case brought by LMA in October 2007 According to decision announced by US court in June 2009 Ambu is not violating LMA’s patent with three product families The case is expected to be concluded around the new year 2009/10 Patent cases in Europe Decision by EPO in February 2008 concerning the invalidation of LMA’s European patent appealed by LMA Appeal expected to be decided at the beginning of 2010 LMA’s utility model patent has been upheld in Germany, but it has been specified how the panel of judges interprets the patent

Questions

For further information, please visit For further information, please contact: Lars Marcher, CEO, or Anders Arvai, CFO, or